Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Economic Development,
Foreign Affairs,
Government Procurement,
Health,
Industry,
International Relations,
International Trade,
National Security/Security,
Science and Technology
|
Canadian-United States-Mexico Agreement (CUSMA) with respect to provisions relating to medical devices and technologies
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Budget,
Federal-Provincial Relations,
Government Procurement,
Health,
Industry
|
Discuss policies around healthcare system resiliency, infection prevention, medication errors, women's health, and health equity
|
Policies or Program,
Regulation
|
Economic Development,
Federal-Provincial Relations,
Government Procurement,
Health,
Industry,
Science and Technology,
Taxation and Finance
|
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, women’s health, and investments in long-term care and home care
|
Legislative Proposal, Bill or Resolution
|
Economic Development,
Government Procurement,
Health,
Industry,
Science and Technology
|
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
|
Policies or Program
|
Economic Development,
Government Procurement,
Health,
Industry,
International Trade,
Research and Development,
Science and Technology
|
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Federal-Provincial Relations,
Health,
Industry
|
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing.
|
Policies or Program
|
Economic Development,
Health,
Industry,
Research and Development,
Science and Technology
|
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
|
Policies or Program
|
Health,
Industry,
Science and Technology
|
Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies
|
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Discuss policies around anti-microbial resistance, infection prevention and medication errors
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal budget with respect to public sector investments in long-term care and home care
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, and women’s health.
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal budget with respect to public sector investments in long-term care and residential care
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal budget with respect to science and technology in the healthcare sector, specifically with respect to medical technology and devices
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal healthcare strategy with respect to COVID-19
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal healthcare strategy with respect to diabetes, cancer testing and long-term care
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal healthcare strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and laboratory diagnostic testing
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal initiatives with respect to the Canadian Life Sciences strategy and intergovernmental policy, funding, legislative, and guideline changes.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal science & technology strategy with respect to medical technology, specifically focusing on accelerating innovation to improve health and economic outcomes
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal science & technology strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
North American Free Trade Agreement (NAFTA) , with respect to provisions relating to medical devices and technologies
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies
|
Regulation
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-03-25 |
|
Economic Development, Health, Science and Technology |
2024-02-13 |
|
Economic Development, Government Procurement, Health, Industry, Research and Development, Science and Technology |
2024-02-05 |
|
Economic Development, Health, Research and Development, Science and Technology |